Trial Profile
An open-label, randomized, controlled, multi-center, Phase II trial comparing Panitumumab versus Bevacizumab in combination with oxaliplatin - 5 FU (FOLFOX) first-line treatment according Ras Wild Type status for patients with metastatic unresectable colorectal cancer (mCRC).
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 02 Feb 2023
Price :
$35
*
At a glance
- Drugs Panitumumab (Primary) ; Bevacizumab; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms PANIB
- 30 Jan 2023 Results assessing value of NPY methylation analysis in circulating tumor DNA for accurate response monitoring in metastatic colorectal cancer patients, published in the Clinical Cancer Research.
- 21 Sep 2020 Results (n=40) presented at the 45th European Society for Medical Oncology Congress
- 31 Dec 2014 New trial record